Instil Bio, Inc. (TIL) Key Metrics
TIL valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $40.1M
- Enterprise value
- $66.8M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 0.5 10-yr median 0.6
- EV / EBITDA
- 0.6
- Dividend yield
- —
- Beta
- 1.94
TIL key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsTIL valuation Price multiples at each fiscal year-end price.
TIL returns How much profit the business earns on the capital it uses.
TIL per-share figures Results divided by the shares outstanding at year-end.
TIL financial health Debt, liquidity and how easily interest is covered.
TIL efficiency & capital use Working capital cycle and where the cash goes.
TIL valuation history
TIL returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
TIL debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
TIL price vs earnings per share
TIL key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $73.4M | $124.3M | $49.6M | $81.6M | $1.81B | — | — |
| Enterprise value | $82.4M | $97.8M | −$14.7M | −$99.4M | $1.36B | — | — |
| Price / book | 0.6 | 0.7 | 0.2 | 0.2 | 3.3 | — | — |
| Earnings yield | −97.3% | −59.7% | −314.9% | −273.5% | −8.6% | — | — |
| Free cash flow yield | −49.9% | −52.9% | −207.2% | −324.5% | −9.9% | — | — |
| Shareholder yield (dividends + buybacks) | — | — | — | — | 0.0% | — | — |
| Share price at fiscal year-end | $11.00 | $19.09 | $7.62 | $12.60 | $342.20 | — | — |
| Per share | |||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.02 | $0.00 |
| Earnings per share | −$10.70 | −$11.39 | −$24.00 | −$34.46 | −$29.59 | −$5.89 | −$1.01 |
| Operating cash flow per share | −$5.49 | −$8.56 | −$12.61 | −$27.82 | −$23.05 | −$4.62 | −$0.83 |
| Free cash flow per share | −$5.49 | −$10.09 | −$15.79 | −$40.88 | −$33.96 | −$12.55 | −$0.94 |
| Cash per share | $11.42 | $17.41 | $23.12 | $40.29 | $85.68 | $37.71 | $1.39 |
| Book value per share | $17.08 | $26.03 | $34.72 | $56.15 | $104.76 | $45.61 | $1.26 |
| Tangible book value per share | $17.08 | $26.03 | $34.72 | $56.15 | $101.78 | $43.14 | $1.26 |
| Capex per share | $1.50 | $1.54 | $3.18 | $13.06 | $10.91 | $7.93 | $0.12 |
| Debt per share | $12.77 | $13.35 | $13.23 | $12.34 | — | — | — |
| Shares outstanding | 6.7M | 6.5M | 6.5M | 6.5M | 5.3M | 6.4M | 6.4M |
| Change in shares outstanding | +2.4% | +0.1% | +0.4% | +22.2% | −17.3% | 0.0% | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | −50.4% | −37.5% | −53.0% | −48.6% | −37.0% | −25.1% | −80.1% |
| Return on invested capital (ROIC) | −31.4% | −38.2% | −73.1% | −114.8% | −162.0% | −106.7% | — |
| Return on assets (ROA) | −30.6% | −25.2% | −38.6% | −40.9% | −33.8% | −23.0% | −68.1% |
| Return on tangible assets | −35.1% | −28.1% | −47.9% | −46.3% | −26.4% | −12.4% | −68.1% |
| Financial health | |||||||
| Total debt | $85.2M | $86.9M | $86.1M | $79.9M | — | — | — |
| Cash & short-term investments | $76.1M | $113.3M | $150.4M | $260.9M | $454.1M | $241.7M | $8.9M |
| Net debt | $9.0M | −$26.4M | −$64.3M | −$181.0M | −$454.1M | −$241.7M | −$8.9M |
| Debt / equity | 0.75 | 0.51 | 0.38 | 0.22 | — | — | — |
| Debt / assets | 0.42 | 0.33 | 0.26 | 0.17 | — | — | — |
| Current ratio | 39.53 | 15.76 | 15.22 | 8.22 | 11.22 | 18.53 | 6.54 |
| Quick ratio | 39.53 | 15.76 | 15.22 | 8.22 | 11.22 | 18.44 | 6.54 |
| Interest coverage | -9.1 | -8.2 | -30.6 | -109.5 | -99.9 | -10.2 | — |
| Working capital | $186.6M | $116.6M | $150.2M | $236.6M | $422.7M | $232.9M | $7.9M |
| Invested capital | $122.9M | $143.0M | $161.5M | $182.6M | $101.1M | $50.7M | −$839,000 |
| Tangible asset value | $113.9M | $169.4M | $225.8M | $363.6M | $539.4M | $276.5M | $8.1M |
| Net current asset value | $101.8M | $30.3M | $61.0M | $150.9M | $409.2M | $219.5M | $7.9M |
| Graham net-net per share | −$1.93 | $3.25 | $7.77 | $21.99 | $76.50 | $34.01 | $1.17 |
| Capital allocation | |||||||
| Share buybacks (net) | — | — | — | — | $0 | — | — |
| Capex / revenue | — | — | — | — | — | 36,823.2% | — |
| Capex / depreciation | 18.73 | 2.77 | 4.34 | 14.13 | 21.01 | 198.50 | 38.00 |
| Stock-based compensation / revenue | — | — | — | — | — | 1,236.2% | — |
| R&D / revenue | — | — | — | — | — | 14,057.2% | — |
| SG&A / revenue | — | — | — | — | — | 10,422.5% | — |
| Efficiency | |||||||
| Days sales outstanding | — | — | — | — | — | 8,392.4 | — |
| Days payables outstanding | 491.5 | 94.6 | 137.0 | 241.6 | 601.0 | — | 17,866.8 |
| Receivables turnover | 0.00 | 0.00 | — | — | 0.00 | 0.04 | — |
| Payables turnover | 0.74 | 3.86 | 2.66 | 1.51 | 0.61 | 0.00 | 0.02 |
| Inventory turnover | — | — | — | — | — | 0.00 | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $1.7M | $2.6M | — | — | $5.7M | $3.2M | — |
| Average payables | $719,000 | $935,500 | $1.8M | $4.0M | $4.5M | $2.2M | $979,000 |
| Average inventory | — | — | — | — | — | $1.2M | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 2.6% | 5.0% | 0.0% |
Computed from TIL's annual financial statements (latest annual report filed March 27, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
TIL valuation and financial ratios
Instil Bio earned a return on equity of −50.4% and a return on invested capital of −31.4% in fiscal 2025. It ended the year with $85.2 million of debt and $76.1 million in cash and short-term investments, net debt of $9.0 million. The share count rose 4.0% from 6.4M to 6.7M over 6 years.
See the TIL income statement, the TIL chart for price history, or the TIL stock overview for the latest quote and news.
TIL key metrics FAQ
What is Instil Bio's return on equity?
Instil Bio's return on equity (ROE) was −50.4% in fiscal 2025: net income of -$71.4 million on average shareholders' equity of $141.7 million.
What is Instil Bio's ROIC?
Instil Bio's return on invested capital was −31.4% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Instil Bio have?
Instil Bio had total debt of $85.2 million at the end of fiscal 2025, a debt-to-equity ratio of 0.75.
What is Instil Bio's free cash flow yield?
Instil Bio generated -$36.6 million of free cash flow in fiscal 2025, a free cash flow yield of −49.9% on its market value at year-end ($73.4 million).
What is Instil Bio's current ratio?
Instil Bio's current ratio was 39.53 at the end of fiscal 2025: current assets were 39.53 times current liabilities.